Uptravi consistent efficacy
REFERENCES
1. Gaine S, Chin K, Coghlan G, et al. Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension. Eur Respir J. 2017; 50(2).
2. Sitbon O, Channick R, Chin KM, et al; For the GRIPHON invitigator. Selexipag for the treatment of pulmonary arterial hypertension.The new England journal of medicine. 2015; 373(26): 2522 - 2533.
3. Gaine S, Chin K, Coghlan G, et al. Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension. Eur Respir J. 2017; 50(2). (supplementary material: Figure S1) https://erj.ersjournals.com/content/50/2/1602493#sec-13. Accessed September 2020.
4. Beghetti M, Channick RN, Chin km, et al. Selexipag treatment for pulmonary arterialhypertension associated with congenital heart disease after defect correction: insights from the randomised controlled GRIPHON study. European Journal of Heart Failure. 2019; 21: 352–359.
CP-266795
